Zymeworks develops antibody-based medicines, with a focus on multispecific biologics for cancer and other serious diseases. Its proprietary Azymetric platform engineers antibodies that can bind multiple targets or sites in controlled geometries. The company advances its own pipeline and partners technology and product candidates with larger pharmaceutical firms.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 48.7 | — | 2.3 | — |
| Q3 2025 | 27.6 | — | -19.6 | — |
| Q4 2025 | 2.5 | — | -41.2 | — |
| Q1 2026 | 2.4 | — | -44.2 | — |
| Q2 2026 | 4.6 | -90.6% | -45 | -2,043% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Perdoceo Education Corporation (PRDO), Allegiant Travel Company (ALGT), Polibeli Group Ltd (PLBL), Establishment Labs Holdings Inc. (ESTA), Nanobiotix S.A. (NBTX), 1st Source Corporation (SRCE)